



Policy Updates – Second Quarter 2024

NEW DRUG SPECIFIC POLICIES *Effective 7/1/2024*

Amtagvi (lifileucel) intravenous suspension	Exblifep® (cefepime and enmetazobactam)	Rezdiffra (resmetirom)
Beqvez (fidanacogene elaparvovec-dzkt)	Lenmeldy (atidarsagene autotemcel)	Voydeya (danicopan)
Duvyzat (givinostat) oral suspension	Olumiant (baricitinib)	Wegovy (<i>effective 4/1/2024</i>)
Eohilia (budesonide)	Opsynvi® (macitentan and tadalafil)	Winrevair (sotatercept-csrk)
		Xolremdi (mavorixafor)

EXISTING DRUG SPECIFIC POLICIES WITH CLINICAL CHANGES *Effective 7/1/2024*

Ampyra (dalfampridine)	Isturisa (osilodrostat) tablets	Skyclarys
BDAID in office administered (<i>effective 8/1/2024</i>)	Koselugo (selumetinib)	Spevigo (spesolimab-sbzo)
BDAID self-administered	Mekinist® (trametinib) tablets	Syfovre (pegcetacoplan injection)
Camzyos (mavacamten)	Nexletol and Nexlizet	Tafinlar (dabrafenib)
Diabetic Supply	Nucala	Tepezza
Emflaza (deflazacort)	Ogsiveo	Tyvaso (treprostinil)
Fasenra (benralizumab)	Omisirge	Ultomiris (ravulizumab-cwvz)
Fotivda	Opsumit	Uptravi (selexipag)
Gattex® (teduglutide)	Orenitram	Ventavis (iloprost) Inhalation Solution
Imbruvica™ (ibrutinib)	PCSK9 Inhibitor Policy – Applies to Praluent (alirocumab) and Repatha (evolocumab)	Weight loss medications
Imlygic (talimogene laherparepvec)		Xolair

Intra-articular Injections of Hyaluronate Products: Please note, medical necessity criteria revised to allow coverage for the diagnosis of osteoarthritis of the knee. <i>(effective 8/1/2024)</i>	Remodulin	Zelapar (seligiline HCl) Orally Disintegrating Tablets
	Rinvoq	Zeposia
	Risperidone long-acting injection	Zometa (zoledronic acid 4mg)
Isotretinoin (Applies to Amnesteem, Claravis®, Zenatane, Absorica® and Absorica LD)	Samsca	

EXISTING DRUG SPECIFIC POLICIES WITH ADMINISTRATIVE CHANGES *Effective 7/1/2024*

Adzynma (ADAMTS13, recombinant-krhn)	High Risk Medications in the Elderly	MS Disease Modifying Therapies Applies to Avonex® (Interferon beta-1a), Glatiramer, Rebif® (Interferon beta-1a), Plegridy® (Peginterferon beta-1a), Glatopa (glatiramer acetate)
Boniva Injection (ibandronate)	IVIG	
Carbaglu (carglumic acid)	Izervay	Pylera- CHP
Cyclosporine Ophthalmic Drops – Applies to Cequa, Restasis and Vevye	Korlym® (mifepristone)	Signifor SQ and Signifor LAR
Descovy (emtricitabine and tenofovir alafenamide) tablets	Lamzede (velmanse alfa-tycv)	Sublingual Allergy Immunotherapy (Applies to Grastek®, Odactra, Oralair® and Ragwitek®)
Desoximetasone 0.05% cream	Litfulo (ritlecitinib)	Tezspire
Dupixent	Luxturna (voretigene neparvovec-rzyl)	Thiola (tiopronin) and Thiola EC (tiopronin delayed-release)
Firvanq	Methotrexate Subcutaneous Injection	Vowst
High Potency Narcotic Step Therapy Policy	Migraine Medication Dosage Limitation Policy for 5-HT1 Receptor Agonists	Ztalmy

EXISTING DRUG SPECIFIC POLICIES REVIEW ONLY/NO CHANGES

Abilify Asimtufii	InPen	Sabril and Vigadrone (vigabatrin)
Afinitor and Afinitor Disperz	Jelmyto	Serostim
Amondys 45	Joenja	Siklos
Arazlo	Ketoconazole	Sodium Phenylbutyrate (Applies to Buphenyl, Olpruva and Pheburane)
Arcalyst	Kitabis Pak	Soolantra
Bafiertam	Levocarnitine	Spravato
Benlysta	Lumryz	State Plans: Sexual and ED Medications
Briviact	Mepsevii	Sucraid
Cablivi	Modified Solid Food Products Coverage	Symdeko
Crysvita	Myalept	Synarel
Cystadane (betaine anhydrous for oral solution)	Mytesi	Tazorac Cream/Gel (tazarotene)
Cystagon	Natpara	Tetrabenazine
Daybue	Northera (droxidopa)	Topical Dermatologic Medications – State Plans
Dayvigo	Nuedexta	Trogarzo
Deferasirox	Nulibry	Vesicare LS oral suspension
Duopa	Onychomycosis – topical treatments	Vijoice
Doxycycline Monohydrate Oral Suspension	Opdualag	Vivjoa
Durysta	Oriahnn	Vonjo
Empaveli	Osmolex ER	Vraylar

Enteral Formula- State Plans	Ozurdex	Vuity
Eucrisa	Palforzia	Vyondys 53
Exondys 51	Phenoxybenzamine	Xiaflex
Filspari	Ponvory	Xuriden
Fingolimod – Applies to Gilenya and Tascenso ODT	Pyrukynd	Zavesca
Hetlioz	Qalsody	Zerbaxa
Horizant	Qelbree	Zinplava
Hyftor	Qinlock	Zoladex
Ilaris	Relistor	Zontivity
Inbrija	Retevmo	Zulresso
Ingrezza	Rezzayo	Zynyz

EXISTING ADMINISTRATIVE POLICIES WITH CHANGES

Experimental or Investigational Treatment Utilization Review Decisions
P&T Committee Integrity Policy

EXISTING ADMINISTRATIVE POLICIES REVIEW ONLY/NO CHANGES

Pharmacy Audit
Pharmacy Authorization Timeliness Policy- Medicaid and Child Health Plus
Specialty Pharmacy - Minimum Terms and Conditions Policy

POLICIES TO BE ARCHIVED

Aduhelm	Non-Participating Prescribers of Emergency Room or Discharge Prescriptions	Tabrecta Tagrisso
Aduhelm FEHB		
Aduhelm - State Products	Pemazyre	Tukysa
Calquence	Relyvrio (sodium phenylbutyrate and taurursodiol)	Uzedy
Levalbuterol HCl Inhalation Solution	Rubraca	Verzenio Zorbtive

PBD ONLY NEW DRUG SPECIFIC POLICIES *Effective 7/1/2024*

BDAID for self-administration	Rubraca	Tukysa
Calquence	Tabrecta	Verzenio
Pemazyre		

PBD EXISTING DRUG SPECIFIC POLICIES WITH CLINICAL CHANGES *Effective 7/1/2024*

Bravtovi	Mektovi	Weight Loss Medications for LMHF
Intra-articular Injections of Hyaluronate Products	Tasigna	Weight Loss Medications-CC
	Weight Loss Medications	

PBD EXISTING DRUG SPECIFIC POLICIES WITH ADMINISTRATIVE CHANGES *Effective 7/1/2024*

Diclofenac for oral solution

PBD EXISTING DRUG SPECIFIC POLICIES REVIEW ONLY/NO CHANGES

Erleada
Sucraid

MAGELLAN RX MANAGEMENT DRUG SPECIFIC CUSTOM POLICY UPDATES *Effective 2/1/2024*

Orencia® (abatacept)
Tocilizumab: Actemra®; Tofidence™ (Intravenous)

MAGELLAN RX MANAGEMENT DRUG SPECIFIC CUSTOM POLICY UPDATES *Effective 5/31/2024*

LA GCSFs

MAGELLAN RX MANAGEMENT DRUG SPECIFIC CUSTOM POLICY UPDATES *Effective 8/1/2024*

Hyaluronic Acid Derivatives (Please note, medical necessity criteria revised to allow coverage for the diagnosis of osteoarthritis of the knee.)

MAGELLAN RX MANAGEMENT EXISTING DRUG SPECIFIC POLICIES W/ CLINICAL CHANGES

Pharmacy PA Only *Effective 5/3/2024*

Tagrisso

Pharmacy PA Only *Effective 5/31/2024*

Benlysta_SQ	Lynparza	Turalio
Brukinsa	Rubraca	Xospata
Iclusig	Rydapt	Zejula
Imbruvica	Talzenna	

Pharmacy PA Only Effective 6/28/2024

Alecensa	Nubeqa	Xalkori
Alunbrig	Pemazyre	Xermelo
Erleada	Pomalyst	Xtandi
Lorbrena	Retevmo	Zykadia
Ninlaro		

PSCE Only Effective 5/1/2024

Fosaprepitant IV
Zoladex

PSCE Only Effective 6/1/2024

Gemcitabine
Injectafer

Medical Pharmacy Effective 6/28/2024

Fasenra

Medical PA Only Effective 5/3/2024

Anti-Inhibitor_Ab	Libtayo	Tivdak
Blincyto	Margenza	Trastuzumab_SQ
Bortezomib	Monjuvi	Trodelvy
Fulvestrant	Phesgo	Vectibix
Jemperli	Rituximab_SQ	Zaltrap
Keytruda	Sarclisa	Zepzelca
Levoleucovorin	Tecentriq	Zynlonta

Medical PA Only Effective 5/31/2024

ACTH	Provenge	Cyramza
Akynzeo IV	Reblozyl	Darzalex IV
Alpha-1 PI	Rybrevant	Darzalex_SQ
Benlysta_IV	Sandostatin_LAR	Erbix
Cabazitaxel	Saphnelo	Gazyva
Cosela	Sustol	Kyprolis
Denosumab	Tocilizumab IV	Opdivo
Elzonris	Zoledronic_Acid	Pemetrexed
Evenity	Adcetris	Perjeta
Factor IX	Beleodaq	Rituximab_IV
GCSF-LA	Bendamustine	Trastuzumab_IV
GCSF-SA	Bevacizumab ONCO	Yervoy
Leukine		

Medical PA Only Effective 6/28/2024

Aranesp	Ryplazim	Imfinzi
Empaveli	Soliris	Kadcyla
Entyvio IV	Ultomiris	Onivyde
Epoetin_alfa	Uplizna	Paclitaxel Albumin-Bound

Imlygic
Jelmyto
Mircera

Besponsa
Empliciti
Halaven

Portrazza
Yondelis